⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibezapolstat SCHEMBL29357391 | 1.00 | — | — | |
| Ibezapolstat SCHEMBL15908913 | 0.99 | — | — | |
| SCHEMBL12173570 | 0.95 | — | — | |
| SCHEMBL1443265 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL15909144 | 0.95 | — | — | |
| SCHEMBL1443301 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL1443775 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL1443761 | 0.94 | — | — | |
| SCHEMBL1443553 | 0.93 | — | — | |
| SCHEMBL1443493 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796292-B2 | Selective antibacterials for clostridium difficile infections | GLSYNTHESIS INC. (US) | 2014-08-05 | — | — | US | claimed |
| US-20240316058-A1 | Use of Ibezapolstat to Promote Microbiome Health | Acurx Pharmaceuticals, Inc. | 2024-09-26 | — | — | US | disclosed |
| US-12036225-B2 | Use of ibezapolstat to promote microbiome health | Acurx Pharmaceuticals, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-117813085-A | Use of Bei Zabo erstat for promoting microbiome health | 阿科利斯制药股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4340827-A2 | USE OF IBEZAPOLSTAT TO PROMOTE MICROBIOME HEALTH | Acurx Pharmaceuticals, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220409625-A1 | Use of Ibezapolstat to Promote Microbiome Health | Acurx Pharmaceuticals, Inc. | 2022-12-29 | — | — | US | disclosed |
| WO-2022266318-A2 | USE OF IBEZAPOLSTAT TO PROMOTE MICROBIOME HEALTH | ACURX PHARMACEUTICALS LLC (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220024925-A1 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | ACURX PHARMACEUTICALS, LLC | 2022-01-27 | — | — | US | disclosed |